Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta‐analysis

Abstract

To cite this article: Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011; 9: 653-63. Summary. Introduction: The incidence of venous thromboembolism (VTE) in patients with multiple myeloma (MM) treated with thalidomide-and lenalidomide-based regimens is high. Recent observational studies have suggested that thromboprophylaxis might be efficacious in decreasing the risk of VTE in this population. Purpose: To determine the absolute rates of VTE with and without different thromboprophylactic agents in patients with newly diagnosed or previously treated MM receiving thalidomide-or lenalidomide-based regimens. Results: Patients with newly diagnosed MM treated with thalidomide in combination with dexamethasone have a VTE risk of 4.1 (95% CI, 2.8-5.9) per 100 patient-cycles. Therapeutic doses of anticoagulants seem to provide the largest absolute risk reduction of VTE. The rate of VTE in patients with previously treated MM receiving thalidomide in combination with dexamethasone is 0.8 (95% CI, 0.1-2.1) per 100 patientmonths. A combination of lenalidomide and dexamethasone is associated with of risk of VTE of 0.8 (95% CI, 0.07-2.0) per 100 patient-cycles and 0.7 (95% CI, 0.4-0.9) per 100 patientcycles in patients with newly diagnosed and previously treated MM, respectively. Similarly, the rates of VTE in patients also receiving thromboprophylaxis with aspirin were 0.9 (95% CI, 0.5-1.5) and 0.6 (95% CI, 0.01-2.1), respectively. Conclusion: Patients with newly diagnosed or previously treated MM receiving thalidomide-or lenalidomide-based regimens in combination with dexamethasone are at high risk of VTE. The benefit of various types of thromboprophylaxis is difficult to quantify in patients with MM receiving immunomodulatory therapy, especially in those receiving lenalidomide-based therapy or who have previously treated MM. Randomized controlled trials are needed to address this important clinical need.

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera

“…110 This should be carefully followed, as novel therapeutics for other conditions, for example, thalidomide-and lenalidomide-based regimen in treatment of multiple myeloma, significantly increase the risk of venous thrombosis. 112 …”

Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin’s lymphoma: A prospective study of 46 cases

“…Oral thalidomide is easy to administer, cost-effective and has tolerable side effects; therefore, its application in clinical practice is feasible and convenient. It has been, however, associated with an increased risk of venous thromboembolism (40). In our study, the median dose of oral thalidomide was 200 mg daily.…”

Lenalidomide in Multiple Myeloma—A Practice Guideline

“…After full text screening, fifty-two publications were included: two practice guidelines 4,5 ; three systematic reviews [6][7][8] ; ten unique primary studies, of which five were full-text publications 1,2,9-11 and five were conference abstracts [12][13][14][15][16] . Forty-two publications were ancillary to the ten unique primary studies, including secondary analyses or follow-up data from the main publications (Table i).…”